Relationship between pulmonary function and albuminuria in type 2 diabetic patients with preserved renal function

Yun-Yun He 1, Zhe Chen 2, Xiang-Yang Fang 1, Jing Chang 1, Yong Lu 3 and Xiao-Juan Wang 1*

Abstract

Background: Albuminuria is the early manifestation of the pathogenesis of diabetic nephropathy (DN). The current study was to investigate the relationship of pulmonary function with albuminuria in type 2 diabetic patients with preserved renal function to evaluate the role of pulmonary function in the early stage of DN.

Methods: A total of 326 patients with type 2 diabetes mellitus (T2DM) including 270 without albuminuria and 56 with albuminuria, and 265 non-diabetic patients were enrolled. The patients' general information, and the parameters of pulmonary function, including forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), FEV1/FVC, total lung capacity (TLC), diffusion capacity for carbon monoxide of lung (DLCO) were compared between T2DM and control groups, as well as T2DM patients with and without albuminuria groups. All pulmonary function parameters were expressed as a percentage of those predicted (%pred). Logistic regression models were constructed to test the association of albuminuria and pulmonary function.

Results: The values of FVC%pred, FEV1%pred, TLC%pred and DLCO%pred were lower, and the proportion of subjects with FVC%pred < 80, FEV1%pred < 80, and DLCO%pred < 80 was higher in T2DM subjects than controls (all P < 0.05). Subgroup analysis of diabetic patients showed that the values of FVC%pred, FEV1%pred, TLC%pred, and DLCO%pred (97.18 ± 13.45, 93.95 ± 14.51, 90.64 ± 9.97, 87.27 ± 13.13, respectively) were significantly lower in T2DM subjects with albuminuria than those without albuminuria (103.94 ± 14.12, 99.20 ± 14.25, 93.79 ± 10.36, 92.62 ± 13.45, all P < 0.05). There was a significantly negative correlation between the urine albumin-to-creatinine ratio (UACR) and DLCO%pred (r = −0.143, P = 0.010) in spearman linear correlation test. In logistic regression analysis, the FVC%pred (OR 0.965, 95%CI 0.944–0.988), FEV1%pred (OR 0.975, 95%CI 0.951–0.998), and DLCO%pred (OR 0.974, 95%CI 0.951–0.998) were independently associated with albuminuria after adjustments for smoking index, duration, HbA1c, FBG, and TG.

Conclusion: Our results demonstrated albuminuria is associated with a restrictive pulmonary function as well as pulmonary diffusion function in T2DM with preserved renal function, which remind us to be alert of the pulmonary function decline even in the early stage of DN.

Keywords: Type 2 diabetes mellitus, Pulmonary function, Albuminuria, Preserved renal function

* Correspondence: xjwang730715@sina.com
1 Department of General Internal Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China
Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Type 2 diabetes mellitus (T2DM) is a chronic disease characterized by glucose metabolism disorder. As the disease progresses, it can cause microvascular and macrovascular complications involving kidney, retina, nerve and cardiovascular system. Although the lung has not been listed as a classical target organ for diabetes, the abundant pulmonary alveolar capillary network and connective tissues raise the possibility that the lung may also be affected by chronic hyperglycemia [1]. To date, the findings in the clinical studies about the relationship between pulmonary function and T2DM are controversial. Some studies believe that the clinical value is not significant, and routine pulmonary function testing is not recommended in patients with diabetes [2, 3]. However, more studies support that T2DM has a deleterious effect on pulmonary function [4–6].

Diabetic nephropathy (DN) is one of the most important microvascular complications in T2DM. It’s usually diagnosed in the middle to late stages when the renal function is declined. Albuminuria, as indicated by the urine albumin-to-creatinine ratio (UACR), is the first manifestation of the pathogenesis of DN even with preserved renal function [7]. Additionally, it is also an independent risk factor of cardiovascular events and mortality [8]. Although previous studies have identified a relationship between pulmonary function and UACR as well as chronic kidney disease with reduced estimated glomerular filtration rate (eGFR) [9–11], few studies focus on the T2DM patients with preserved eGFR. As we know, those with T2DM are more likely to have albuminuria and at a higher risk for cardiovascular disease even with preserved eGFR [12]. However, the relationship between the pulmonary function and albuminuria in these groups is unclear.

The aim of our study was to investigate the relationship between pulmonary function and albuminuria in T2DM patients with preserved renal function. Such information would be useful to evaluate the changes of pulmonary function in the early stage of DN.

Methods
Subjects
Three hundred and twenty-six patients with T2DM who were admitted to Department of General Internal Medicine and Endocrinology of Beijing Chao-Yang Hospital from January 2018 to December 2019 were included in this study. The diagnosis of T2DM was according to the criteria of World Health Organization 1999 or treatment with insulin or other hypoglycemic agents. Also, 265 subjects without T2DM were included as controls.

The exclusion criteria were acute infections, renal dysfunction (eGFR < 60 ml/min/1.73 m²), other kidney diseases, occupational dust exposure history, acute and chronic pulmonary basic diseases, cardiac insufficiency, malignant tumors, acute coronary syndrome and acute cerebrovascular diseases within 3 months, thoracic malformation, connective tissue diseases, blood system diseases and acute diabetic ketoacidosis. All subjects underwent biochemistry, chest x-ray or CT, electrocardiogram, and echocardiography to exclude the above conditions. The study was approved by the Ethical Committee for Medical Research of Beijing Chao-Yang Hospital and accorded with Helsinki Declaration. Informed consent was obtained from all subjects.

Clinical data collection
The clinical parameters of the patients, including sex, age, diabetes duration, and smoking status, were collected in detail by face-to-face interview. The height and weight of patients was measured in pulmonary function laboratory by the same gauges. The Body mass index (BMI) was calculated by dividing the weight (in kilograms) by the height (in meters) squared. Smoking status included current smoking, smoking cessation for more than 1 year, and never smoking. Smoking index was defined as the average root number per day multiplied by smoking years.

Biochemical variables were included glycated hemoglobin A1c (HbA1c), fasting blood glucose (FBG), low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL), triglyceride level (TG) and serum creatinine. The eGFR was calculated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [13].

The random urine albumin and urine creatinine were determined by nephelometry in the clinical laboratory. The incident albuminuria was defined as the UACR ≥30 mg/g.

Pulmonary function testing
Spirometry was measured by experienced physicians using Jaeger MasterScreen pulmonary function instrument and all tests were performed according guidelines of pulmonary function professional group of respiratory branch of Chinese medical association. The examination parameters included forced vital capacity (FVC), forced expiratory volume in first second (FEV1), FEV1/FVC, total lung capacity (TLC), diffusion capacity for carbon monoxide (DLCO), alveolar volume (VA) and DLCO/VA. All subjects were required to provide at least three acceptable spirometry curve and 150 ml intermeasurement variability in FVC and FEV1 [14]. DLCO was measured at least twice with a 5-min snooze and 10% intermeasurement variability [15]. All values were expressed as a percentage of those predicted (%pred) for age, sex, height and weight based on data from Chinese general population.
Statistical analysis
All tests were carried out using SPSS version 22.0 statistical software. The continuous variables were shown as mean ± standard deviation or median (minimum, maximum). Statistical analysis of continuous variables was performed using an unpaired Student t test or Mann-Whitney U test between two groups, and by one-way analysis of variance (ANOVA) or Kruskal-Wallis for multiple comparisons. Categorical variables were expressed as frequency and percentages, and performed by chi-square test or Fisher exact test. Spearman linear correlation test was employed to study the association between UACR and pulmonary function parameters. Multivariate logistic regression analysis with forward stepwise method was performed to evaluate the association between pulmonary function and albuminuria, by adjustment the parameters with a P value of less than 0.05 in the univariate analysis. Differences were considered statistically significant at a two-tailed P value < 0.05.

Results
Clinical characteristics and pulmonary function in T2DM and control subjects
A total of 326 T2DM participants and 265 controls were included in this study. The characteristics of T2DM and controls are listed in Table 1. There were no statistically significant differences in sex and age. Patients with T2DM had significantly higher BMI (27.07 ± 3.86 vs 26.31 ± 3.63 kg/m², P = 0.015), lower median smoking index (40 vs 300, P = 0.003), less current smokers (42% vs 54%, P = 0.001) and higher eGFR (105.46 ± 14.20 vs 100.89 ± 11.48 ml/min/1.73m², P = 0.000) than controls.

The pulmonary function tests showed that in T2DM patients, the values of FVC%pred, FEV1%pred, TLC%pred, and DLCOc%pred were (102.78 ± 14.22, 98.30 ± 14.41, 93.24 ± 10.34, 91.7 ± 13.53, respectively) significantly lower than those in controls (107.21 ± 13.05, 101.56 ± 12.67, 97.48 ± 10.17, 94.80 ± 12.83, all P < 0.05). In contrast, the FEV1/FVC% was higher in T2DM patients than controls (78.37 ± 5.46 vs 77.49 ± 4.88, P = 0.043). We also found that the proportion of subjects with FVC%pred < 80, FEV1%pred < 80, and DLCOc%pred < 80 was higher in T2DM than controls (4.0% vs 8.6%, 26% vs 16.6% vs 9.8%, all P < 0.05). There was no statistically difference in DLCOc/VA%pred. (Table 2).

The results of a sub-analysis by smoking status showed that the values of FVC%pred, FEV1%pred, and TLC%pred were significantly lower in T2DM than those in controls for both never smokers (105.48 ± 15.14 vs 112.72 ± 14.09, 100.86 ± 14.74 vs 106.55 ± 14.36, 93.89 ± 11.00 vs 99.40 ± 11.04, all P < 0.05) and former/current smokers (100.29 ± 12.86 vs 104.52 ± 11.63, 95.95 ± 13.73 vs 99.13 ± 11.00, 92.66 ± 9.71 vs 96.55 ± 9.60, all P < 0.05). Also, in the subgroup of never smokers, the DLCOc%pred of T2DM was (91.39 ± 13.53 vs 97.03 ± 14.91, P < 0.05) significantly lower than those in controls. In addition, the FEV1/FVC% was highest in T2DM of never smokers and lowest in current smokers. The DLCOc%pred of T2DM was (91.39 ± 13.53 vs 97.03 ± 14.91, P < 0.05) significantly lower than those in controls. In addition, the FEV1/FVC% was highest in T2DM of never smokers and lowest in current smokers.

### Table 1 Demographic and clinical characteristics of control and T2DM subjects

| Sex          | Controls (n = 265) | T2DM (n = 326) | P   |
|--------------|-------------------|----------------|-----|
| Male, n (%)  | 192(72.5)         | 222(68.1)      | 0.250 |
| Female, n (%)| 73(27.5)          | 104(31.9)      |      |
| Age          | 52.55 ± 10.11     | 53.52 ± 11.57  | 0.282 |
| BMI (kg/m²)  | 26.31 ± 3.63      | 27.07 ± 3.86   | 0.015 |
| Smoking index| 300(0, 2400)      | 40(0, 2400)    | 0.003 |

| Current smoking status | Controls (n = 265) | T2DM (n = 326) | P   |
|------------------------|--------------------|----------------|-----|
| Never, n (%)           | 87(32.8)           | 156(47.9)      | 0.001 |
| Former, n (%)          | 35(13.2)           | 33(10.1)       |      |
| Current, n (%)         | 143(54.0)          | 137(42.0)      |      |
| HbA1c (%)              | 5.54 ± 0.29        | 9.07 ± 2.22    | 0.000 |
| FBG (mmol/L)           | 4.91 ± 0.67        | 7.65 ± 2.66    | 0.000 |
| LDL (mmol/L)           | 1.15 ± 0.32        | 1.02 ± 0.25    | 0.580 |
| TG (mmol/L)            | 2.01 ± 1.44        | 2.16 ± 1.58    | 0.242 |
| eGFR (ml/min/1.73m²)   | 100.89 ± 11.48     | 105.46 ± 14.20 | 0.000 |

Data are presented as mean ± standard deviation, median (minimum, maximum), or number with percentage (%)

BMI = body mass index, HbA1c = glycated hemoglobin A1c, FBG = fasting blood glucose, LDL = low-density lipoprotein cholesterol, HDL = high-density lipoprotein cholesterol, TG = triglyceride level, eGFR = estimated glomerular filtration rate

### Table 2 Pulmonary function data of control and T2DM subjects

|                | Control (n = 265) | T2DM (n = 326) | P   |
|----------------|------------------|----------------|-----|
| FVC%pred      | 107.21 ± 13.05    | 102.78 ± 14.22 | 0.000 |
| < 80, n (%)    | 2 (0.8)           | 13 (4.0)       | 0.026 |
| > 80, n (%)    | 263 (99.2)        | 313 (96.0)     |      |
| FEV1%pred      | 101.56 ± 12.67    | 98.30 ± 14.41  | 0.004 |
| < 80, n (%)    | 7(2.6)            | 32 (9.8)       | 0.001 |
| > 80, n (%)    | 258 (97.4)        | 294 (90.2)     |      |
| FEV1/FVC (%)   | 77.49 ± 4.88      | 78.37 ± 5.46   | 0.043 |
| < 80, n (%)    | 26 (9.8)          | 54 (16.6)      | 0.023 |
| > 80, n (%)    | 239 (90.2)        | 272 (83.4)     |      |
| TLC%pred       | 97.48 ± 10.17     | 93.24 ± 10.34  | 0.000 |
| DlCOc%pred     | 94.80 ± 12.83     | 91.70 ± 13.53  | 0.005 |
| < 80, n (%)    | 26 (9.8)          | 54 (16.6)      | 0.023 |
| > 80, n (%)    | 239 (90.2)        | 272 (83.4)     |      |
| DLCOc/VA%pred  | 99.72 ± 14.06     | 101.61 ± 15.04 | 0.119 |

Data are presented as mean ± standard deviation, or number with percentage (%)

FVC = forced vital capacity, FEV1 = forced expiratory volume in 1 second, TLC = total lung capacity, DLCO = diffusion capacity for carbon monoxide of lung, VA = alveolar volume
controls of former/current smokers (79.21 ± 5.18 vs 76.99 ± 4.83, P < 0.05). (Table S1).

The subgroup analysis of clinical characteristics and pulmonary function in T2DM subjects with or without albuminuria

There were 270 T2DM patients without albuminuria (UACR < 30 mg/g) and 56 with albuminuria (UACR ≥30 mg/g) in this study. No statistically significant differences were found in sex, age, BMI, and smoking status between the two groups. The T2DM patients with albuminuria had longer median duration (7.5 vs 5, P = 0.032), higher HbA1c (9.69 ± 2.58 vs 8.94 ± 2.12, P = 0.021), FBG (8.60 ± 3.22 vs 7.46 ± 2.49 mmol/L, P = 0.003) and TG (2.86 ± 2.14 vs 2.02 ± 1.39 mmol/L, P = 0.000) than those without albuminuria. (Table 3).

The values of FVC%pred, FEV1%pred, TLC%pred, and DLCOc%pred were (97.18 ± 13.45, 93.95 ± 14.51, 90.64 ± 9.97, 87.27 ± 13.13, respectively) significantly lower in T2DM with albuminuria than those without albuminuria (103.94 ± 14.12, 99.20 ± 14.25, 93.79 ± 10.36, 92.62 ± 13.45, all P < 0.05). There were no significant differences in FEV1/FVC% and DLCOc/VA%pred between the two groups. The proportion of subjects with FVC%pred < 80, FEV1%pred < 80, and DLCOc%pred < 80 had an increasing tendency in albuminuria group, but no statistical significance (5.4% vs 3.7%, 16.1% vs 8.5%, 25% vs 14.8%, all P > 0.05). (Table 4).

Moreover, in the sub-analysis by smoking status, T2DM with albuminuria had higher FBG than those without albuminuria for never smokers. The FVC%pred, FEV1%pred, and TLC%pred were highest in group of never smokers-without albuminuria and lowest in former/current smokers-albuminuria. The FVC%pred was significantly lower in T2DM with albuminuria than those without albuminuria for both never smokers (99.84 ± 13.80 vs 106.56 ± 15.20, P < 0.05) and former/current smokers (95.05 ± 12.99 vs 101.46 ± 12.58, P < 0.05). For former/current smokers, the DLCOc%pred of T2DM with albuminuria was lower than those without albuminuria (87.23 ± 12.13 vs 93.05 ± 13.68, P < 0.05). (Table S2).

Correlation of UACR levels with pulmonary function

The correlation of UACR levels with pulmonary function parameters in T2DM subjects was analyzed by spearman linear correlation test. The results are shown in Table 5. There was a significantly negative correlation between UACR and DLCOc%pred (r = −0.143, P = 0.010). There were no statistical correlation between UACR and FVC%pred as well as TLC%pred at a P value of 0.069 and 0.058, respectively.

Multivariate logistic regression analyses for albuminuria

The logistic regression analysis was performed to study the independent associations with albuminuria in T2DM

Table 3 Clinical characteristics of T2DM subjects without or with albuminuria

| Sex       | Without albuminuria (n = 270) | Albuminuria (n = 56) | P     |
|-----------|-------------------------------|----------------------|-------|
| Male, n (%) | 182(67.4)                     | 40(71.4)             | 0.557 |
| Female, n (%)  | 88(32.6)                      | 16(28.6)             |       |
| Age        | 53.72 ± 11.46                 | 52.54 ± 12.13        | 0.487 |
| BMI (kg/m²) | 26.97 ± 3.97                  | 27.55 ± 3.89         | 0.308 |
| Smoking index | 18.5(0, 2400)                | 112.5(0, 2400)       | 0.141 |
| Current smoking status | | | |
| Never, n (%)  | 131(48.5)                     | 25(44.7)             | 0.508 |
| Former, n (%)  | 29(10.7)                      | 4(7.1)               |       |
| Current, n (%)  | 110(40.8)                     | 27(48.2)             |       |
| Duration (year) | 5(0, 30)                      | 7.5(0, 41)           | 0.032 |
| Hba1c (%)  | 8.94 ± 2.12                   | 9.69 ± 2.58          | 0.021 |
| FBG (mmol/L) | 7.46 ± 2.49                   | 8.60 ± 3.22          | 0.003 |
| HDL (mmol/L) | 1.02 ± 0.24                   | 1.01 ± 0.29          | 0.857 |
| LDL (mmol/L) | 2.76 ± 0.90                   | 2.87 ± 1.03          | 0.450 |
| TG (mmol/L) | 2.02 ± 1.39                   | 2.86 ± 2.14          | 0.000 |
| eGFR (ml/min/1.73m²) | 105.48 ± 13.89          | 105.37 ± 15.76       | 0.955 |

Data are presented as mean ± standard deviation, median (minimum, maximum), or number with percentage (%).

BMI body mass index, Hba1c glycated hemoglobin A1c, FBG fasting blood glucose, LDL low-density lipoprotein cholesterol, HDL high-density lipoprotein cholesterol, TG triglyceride level, eGFR estimated glomerular filtration rate.

Table 4 Pulmonary function data of T2DM subjects without or with albuminuria

| | Without albuminuria (n = 270) | Albuminuria (n = 56) | P     |
|---|--------------------------------|----------------------|-------|
| FVC%pred | 103.94 ± 14.12 | 97.18 ± 13.45 | 0.001 |
| FEV1%pred | 99.20 ± 14.25 | 93.95 ± 14.51 | 0.013 |
| DLCOc%pred | 92.62 ± 13.45 | 87.27 ± 13.13 | 0.007 |
| FEV1/FVC (%) | 78.28 ± 5.28 | 78.78 ± 6.31 | 0.584 |
| TLC%pred | 93.79 ± 10.36 | 90.64 ± 9.97 | 0.038 |
| DLCOc/VA%pred | 101.61 ± 14.91 | 101.59 ± 15.80 | 0.992 |

Data are presented as mean ± standard deviation, or number with percentage (%).

FVC forced vital capacity, FEV1 forced expiratory volume in 1 second, TLC total lung capacity, DLCO diffusion capacity for carbon monoxide of lung, VA alveolar volume.
patients (Table 6). We analyzed sex, age, BMI, smoking index, duration, HbA1c, FBG, HDL, LDL, TG, eGFR, FVC%pred, FEV1%pred, FEV1/FVC, TLC%pred, DLCOc%pred, and DLCOc/VA%pred in the univariate logistic regression analysis. The P values of variables including smoking index, duration, HbA1c, FBG, TG, FVC%pred, FEV1%pred, TLC%pred, and DLCOc%pred were less than 0.05.

In the subsequent multivariate logistic regression models, we respectively explored whether the FVC%pred (model 1), FEV1%pred (model 2), DLCOc%pred (model 3), were independent associations with albuminuria, after adjustments for smoking index, duration, HbA1c, FBG, and TG. The results revealed that FVC%pred (OR = 0.965, 95% CI = 0.944–0.988, \( P = 0.002 \)), FEV1%pred (OR = 0.975, 95% CI = 0.954–0.996, \( P = 0.022 \)), and DLCOc%pred (OR = 0.974, 95% CI = 0.951–0.998, \( P = 0.035 \)) were independently associated with albuminuria.

**Discussion**

In the present study, our results verified the point that T2DM exerts a negative effect on pulmonary function manifested as a change of restrictive pulmonary ventilation and diffusion function. We also demonstrated the relationship between the pulmonary function and albuminuria in T2DM with preserved eGFR. We found that FVC%pred, FEV1%pred, and DLCOc%pred were independently associated with albuminuria after adjustments for smoking index, diabetic duration, HbA1c, FBG, and TG.

As a systemic disease, the opinions about the effect of diabetes on pulmonary function are divided. Analysis of current studies shows that most scholars support the existence of pulmonary function changes in diabetic patients, and put forward the concept of “diabetic lung” [16, 17]. The ARIC study including 1100 diabetics and 10,162 controls pointed out that abnormalities in pulmonary function, particularly vital capacity, precede diabetes, then continue after diabetes onset [4]. Also, studies reported that the impairment of diabetic pulmonary function is more reflected in the decline of diffusion function [18, 19]. In addition, a systematic review of 34 articles showed that adults with diabetes mellitus have lower FVC and FEV1, with reductions in FVC more consistent than FEV1 and lower DLCO compared with their non-diabetic counterpart [20]. Recently, a study by Kopf et al. found that diabetic patients are prone to interstitial lung disease [21]. Even in the prediabetes stage, the deleterious effect of T2DM on pulmonary function appears to be initiated [22].

It is generally known that smoking is one of the most critical influences on pulmonary function. In our study, compared with controls, the smoking index and the percentage of current smoking status were both lower in T2DM. Even so, the values of FVC%pred, FEV1%pred, TLC%pred, and DLCOc%pred were significantly lower in T2DM than controls. We further found that the proportion of subjects with FVC%pred < 80, FEV1%pred < 80, and DLCOc%pred < 80 was higher in T2DM than controls. In contrast, because of the smaller magnitude for FEV1 than FVC, there was an inversion of FEV1/FVC.

| Table 5 | Correlation between pulmonary function and UACR in T2DM Group |
|---------|-------------------------------------------------------------|
|         | r            | \( P \)     |
| FVC%pred | -0.101       | 0.069       |
| FEV1%pred | -0.090       | 0.105       |
| FEV1/FVC (%) | 0.020       | 0.714       |
| TLC%pred  | -0.105       | 0.058       |
| DLCOc%pred | -0.143       | 0.010       |
| DLCOc/VA%pred | -0.025       | 0.651       |

FVC: forced vital capacity, FEV1: forced expiratory volume in 1 second, TLC: total lung capacity, DLCO: diffusion capacity for carbon monoxide of lung, VA: alveolar volume

### Table 6: The univariate and multivariate logistic regression analyses for albuminuria

| Smoking index | OR (95% CI) | \( P \) |
|---------------|------------|------|
| OR (95% CI)   | 1.001(1.000–1.001) | 0.040 |
| Duration      | 1.053(1.015–1.096) | 0.006 |
| HbA1c         | 1.156(1.021–1.309) | 0.022 |
| FBG           | 1.155(1.046–1.276) | 0.004 |
| TG            | 1.314(1.120–1.541) | 0.001 |
| FVC%pred      | 0.965(0.944–0.986) | 0.001 |
| FEV1%pred     | 0.974(0.954–0.995) | 0.014 |
| DLCOc%pred    | 0.969(0.948–0.992) | 0.008 |

| Model 1       | OR (95% CI) | \( P \) |
|---------------|------------|------|
| OR (95% CI)   | 1.065(1.022–1.109) | 0.003 |
| Duration      | 1.228(1.068–1.413) | 0.004 |
| HbA1c         | 1.357(1.143–1.610) | 0.000 |
| FBG           | 1.320(1.126–1.571) | 0.001 |
| TG            | 0.975(0.954–0.996) | 0.022 |
| FVC%pred      | 0.969(0.948–0.992) | 0.008 |

| Model 2       | OR (95% CI) | \( P \) |
|---------------|------------|------|
| OR (95% CI)   | 1.061(1.019–1.105) | 0.004 |
| Duration      | 1.224(1.065–1.406) | 0.004 |
| HbA1c         | 1.330(1.126–1.571) | 0.001 |
| FBG           | 0.974(0.954–0.996) | 0.022 |
| TG            | 0.975(0.954–0.996) | 0.022 |

HbA1c: glycated hemoglobin A1c, FBG: fasting blood glucose, TG: triglyceride level, FVC: forced vital capacity, FEV1: forced expiratory volume in 1 second, DLCO: diffusion capacity for carbon monoxide of lung, OR: odds ratio, CI: confidence interval

Model 1: included FVC%pred, smoking index, duration, HbA1c, FBG, and TG
Model 2: included FEV1%pred, smoking index, duration, HbA1c, FBG, and TG
Model 3: included DLCOc%pred, smoking index, duration, HbA1c, FBG, and TG
FVC% in T2DM patients. These results indicated the changes of restrictive pulmonary ventilation and diffusion function in T2DM patients, which are generally consistent with majority of prior studies. In order to further get rid of the effect of smoking on pulmonary function, we then provided a sub-analysis by smoking status. The results also revealed the negative effect of T2DM on pulmonary function in both never smokers and former/current smokers. Also, the FEV1/FVC% was highest in T2DM of never smokers and lowest in controls of former/current smokers, which indicated the more important role of smoking in obstructive pulmonary function. Recently, a prospective study including 7524 participants also reported that diabetes is not associated with obstructive pulmonary function impairment [6]. In addition, some studies with small sample size reported that not only DLCOc%pred but also DLCOc/VA%pred was decreased in T2DM [23, 24]. However, in current study, there was no statistically difference in DLCOc/VA%pred, which may be associated with a decrease in alveolar ventilation (VA) induced by restrictive ventilation dysfunction.

Albuminuria is the best available surrogate parameter in the pathogenesis of DN, which is raised before the decrease of eGFR. On the contrary, the glomerular hyperfiltration is accrued in the early stage of DN [25]. As described in this paper, the eGFR was higher in T2DM subjects than controls. Lee reported that abnormal pulmonary function is associated with increased odds for chronic kidney disease indicators, such as lower eGFR or albuminuria in metabolic syndrome [26]. It is also reported that pulmonary dysfunction, particularly restrictive dysfunction associates with degree of renal function impairment and contributes to the progression of chronic kidney disease [27, 28]. But, it is still unclear whether the pulmonary function is declined or not in DN patients with preserved eGFR. Then, we explored the relationship between pulmonary function with albuminuria in T2DM patients with preserved eGFR, in order to make clear the changes of pulmonary function in the early stage of DN.

In the current study, there was no significant difference of eGFR between T2DM patients with or without albuminuria. The FVC%pred, FEV1%pred, TLC%pred, and DLCOc%pred were significantly lower in T2DM subjects with albuminuria than those without albuminuria. The sub-analysis by smoking status revealed that whether you smoke or not, the presence of albuminuria adversely affected the pulmonary function, especially more so with smokers. The spearman linear correlation test showed that there was a significantly negative correlation between UACR and DLCOc%pred. By multivariate logistic regression, we found that FVC%pred, FEV1%pred, and DLCOc%pred were independently associated with albuminuria after adjustments for smoking index, duration, HbA1c, FBG, and TG.

Albuminuria, which indicates that blood albumin has leaked from blood vessels of the kidneys into the urine, is a strong marker of microvascular damage. Hence, our current finding of an inverse relationship between pulmonary function and UACR is consistent with the evidence that pulmonary microangiopathy is detectable in T2DM subjects [29, 30]. These results remind us even in the early stage of DN, we should be alert of the decline of pulmonary function.

However, the proportion of subjects with FVC%pred < 80, FEV1%pred < 80, and DLCOc%pred < 80 in albuminuria subjects were increased but insufficient to reach statistical significance in the current study. As we know, the pulmonary alveolus-capillary network is the largest microvascular bed with powerfully physiological reserve in the human body [31]. So the change of pulmonary function of T2DM subjects in the early stage of DN is more marked by decline rather than dysfunction. Even so, we still think that it is necessary to carried out pulmonary function tests in T2DM patients whether you smoke or not, especially for those with albuminuria or other microangiopathy [32].

There are some limitations to our study. Firstly, this study was a single-center, cross-sectional study. Therefore, it was not possible to assess changes of pulmonary function over time and the implications of these changes on the T2DM outcomes. Secondly, the number of cases with albuminuria was relatively small, which did not allow subgroup analyses by microalbuminuria and proteinuria. A large-scale investigation about pulmonary function and albuminuria needs to be built to further confirm the relationship.

Conclusions
In conclusions, our results verified the point that T2DM exerts a negative effect on pulmonary function manifested as a change of restrictive pulmonary ventilation and diffusion function. We also demonstrated that albuminuria is associated with a restrictive pulmonary function as well as pulmonary diffusion function in T2DM with preserved eGFR, which remind us to be alert of the decline of pulmonary function even in the early stage of DN.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12902-020-00598-1.

Additional file 1: Table S1. Demographic, clinical characteristics and pulmonary function of control and T2DM subjects by smoking status.
Additional file 2: Table S2. Demographic, clinical characteristics and pulmonary function of T2DM subjects without or with albuminuria by smoking status.

Abbreviations
DN: Diabetic nephropathy; T2DM: Type 2 diabetes mellitus; UACR: Urine albumin-to-creatinine ratio; eGFR: Estimated glomerular filtration rate; CKD-EPI: Chronic kidney disease-Epidemiology collaboration; BMI: Body mass index; HbA1c: Glycated hemoglobin A1c; FBG: Fasting blood glucose; LDL: Low-density lipoprotein cholesterol; HDL: High-density lipoprotein cholesterol; TG: Triglyceride level; FVC: Forced vital capacity; FEV1: Forced expiratory volume in 1 second; TLC: Total lung capacity; DlCO: Diffusion capacity for carbon monoxide of lung; VA: Alveolar volume; OR: Odds ratio; CI: Confidence interval.

Acknowledgments
Not applicable.

Authors’ contributions
HYY was responsible for data collection and analysis, and in writing the manuscript. CZ, FYX and CJ took part in the research implementation and data collection. LY and WXJ were responsible for the design of the study and revised the manuscript. All authors approved the final version of the manuscript.

Funding
This study was supported by Beijing Municipal Administration of Hospitals Incubating Program (No.PX201804) and Capital Medical University Incubating Program (No. PYZ2018029). The funder had no role on the study design, data collection and analysis, and writing the manuscript in this study.

Availability of data and materials
The data that support this study are available from the corresponding author only upon reasonable request, once the study has been published.

Ethics approval and consent to participate
The study was approved by the Ethical Committee for Medical Research of Beijing Chao-Yang Hospital and accorded with Helsinki Declaration. Informed consent was obtained from all subjects.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of General Internal Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China. 2Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China. 3Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.

Received: 24 February 2020 Accepted: 16 July 2020
Published online: 23 July 2020

References
1. Sampol G, Leduc A. Type 2 diabetes and the lung: a bidirectional relationship. Endocrinol Nutr. 2012;59(2):95–7.
2. Ramirez LC, Dal Nogare A, Hsia C, Araúz C, Butt I, Strowig SM, Schnur-Breen L, Raskin P. Relationship between diabetes control and pulmonary function in insulin-dependent diabetes mellitus. Am J Med. 1991;91(4):371–6.
3. Berbassou CA, Stein E, Kramer M, Lezelter J, Blum J, Fink G. Pulmonary function in patients with diabetes mellitus. Am J Med Sci. 2001;322(3):127–32.
4. Yeh HC, Punjabi NM, Wang NY, Pankow JS, Duncan BB, Cox CE, Selvin E, Brancati FL. Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the atherosclerosis risk in communities (ARIC) study. Diabetes Care. 2008;31(4):741–6.
5. Davis TM, Knurman M, Kendall P, Yu H, Davis WA. Reduced pulmonary function and its associations in type 2 diabetes: the Fremantle diabetes study. Diabetes Res Clin Pract. 2000;50(2):153–9.
6. Sonoda N, Morimoto A, Tatsumi Y, Asayama K, Ohkubo T, Iwasa S, Ohno Y. A prospective study of the impact of diabetes mellitus on restrictive and obstructive lung function impairment: the Saku study. Metabolism. 2018;82:58–64.
7. Kishore L, Kaur N, Singh R. Distinct biomarkers for early diagnosis of diabetic nephropathy. Curr Diabetes Rev. 2017;13(6):598–605.
8. Miyake H, Kanazawa I, Sugimoto T. Albuminuria increases all-cause mortality in Japanese patients with type 2 diabetes. J Clin Med. 2018;7(9):234.
9. Yoon JH, Won JU, Ahn YS, Roh J. Poor lung function has inverse relationship with microalbuminuria, an early surrogate marker of kidney damage and atherosclerosis: the 5th Korea National Health and nutrition examination survey. PLoS One. 2014;9(4):e94125.
10. Oelsner EC, Balte PP, Grams ME, Cassano PA, Jacobs DR, Barr RG, Burkart KM, Kalhan R, Kronmal R, Loehrl LR, O’Connor GT, Schwartz JE, Shlipak M, Tracy RP, Tsai MY, White W, Yende S. Albuminuria, lung function decline, and risk of incident chronic obstructive pulmonary disease. The NHLBI pooled cohorts study. Am J Respir Crit Care Med. 2019;199(3):321–32.
11. Nakade Y, Toyama T, Furuschi K, Kitajima S, Ohkura N, Sagara A, Shinozaki Y, Hara A, Kitagawa K, Shimizu M, Iwata Y, Oe H, Nagahara M, Horita H, Sakai Y, Kaneko S, Wada T. Impact of kidney function and urinary protein excretion on pulmonary function in Japanese patients with chronic kidney disease. Clin Exp Nephrol. 2014;18(5):763–9.
12. De Cosmo S, Rossi MC, Pellegrini F, Lucisano G, Bacci S, Gentile S, Ceriello A, Russo G, Nicolucci A, Giorda C, Vazzi F, Pontremoli R. Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes. Nephrol Dial Transplant. 2014;29(3):657–62.
13. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coreth J. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.
14. Pulmonary function professional group of respiratory branch of Chinese medical association. Guidelines for lung function test (Part II) - spirometry examination. Chin J Tuberc Respir Dis. 2014;37(7):481–6.
15. Pulmonary function professional group of respiratory branch of Chinese medical association. Guidelines for lung function test – lung diffusion function examination. Chin J Tuberc Respir Dis. 2015;38(3):164–9.
16. Leduc B, Simo R, Pallayova M, Punjabi NM, Lopez-Cano C, Turino C, Hernandez C, Barbe F. Pulmonary function and sleep breathing: two new targets for type 2 diabetes care. Endocr Rev. 2017;38(6):550–73.
17. Pitocco D, Fusco L, Conte EG, Zaccardi F, Condoluci C, Scavone G, Incalzi RA, Ghirlanda G. The diabetic lung—a new target organ? Rev Diabet Stud. 2012;9(1):23–35.
18. Klein OL, Kalhan R, Williams MM, Tipping M, Lee J, Peng J, Smith LJ. Lung spirometry parameters and diffusion capacity are decreased in patients with type 2 diabetes. Diabet Med. 2012;29(2):212–9.
19. Chance WW, Reeve C, Yilmaz C, Dame DM, Pruneda ML, Raskin P, Hsia CC. Diminished alveolar macrovascular reserves in type 2 diabetes reflect systemic microangiopathy. Diabetes Care. 2008;31(8):1596–601.
20. Klein OL, Krishnan JA, Glick S, Smith LJ. Systematic review of the association between lung function and type 2 diabetes mellitus. Diabet Med. 2010;27(9):977–87.
21. Kopf S, Gruener JB, Kender Z, Fleming T, Brune M, Redinger C, Volk N, Herpel E, Pesta D, Szenodori J, Wielputz MO, Kauczor HU, Katus HA, Kreuter M, Nawroth PP. Breathlessness and restrictive lung disease. An important diabetes-related feature in patients with type 2 diabetes mellitus. J Diabetes Res. 2013;7(9):1874–7.
22. Sanchez E, Gutierrez-Carrasquilla L, Barbe F, Betru A, Lopez-Cano C, Gaeta AM, Purroy F, Pamplona R, Ortega M, Fernandez E, Hernandez C, Leduc B, Simon R. Lung function measurements in the prediabetes stage: data from the ILERVAS Project. Acta Diabetol. 2019;56(9):1005–12.
23. Saler T, Cakmak G, Saglam ZA, Ataoglu E, Yesim Erdem T, Yenigun M. The diabetic lung-a new target organ? Rev Diabet Stud. 2012;9(1):23–35.
26. Lee K. Lung function and impaired kidney function in relation to metabolic syndrome. Int Urol Nephrol. 2017;49(7):1217–23.
27. Mukai H, Ming P, Lindholm B, Heimburger O, Barany P, Stenwinkel P, Qureshi AR. Lung dysfunction and mortality in patients with chronic kidney disease. Kidney Blood Press Res. 2018;43(2):522–35.
28. Sumida K, Kviak L, Grams ME, Yamagata K, Punjabi NM, Kovesdy CP, Coresh J, Matsushita K. Lung function and incident kidney disease: the atherosclerosis risk in communities (ARIC) study. Am J Kidney Dis. 2017;70(5):675–85.
29. Roberts TJ, Burns AT, MacIsaac RJ, MacIsaac AI, Prior DL, La Gerche A. Diagnosis and significance of pulmonary microvascular disease in diabetes. Diabetes Care. 2018;41(4):854–61.
30. Agarwal AS, Fuladi AB, Mishra G, Tayade BO. Spirometry and diffusion studies in patients with type-2 diabetes mellitus and their association with microvascular complications. Ind J Chest Dis Allied Sci. 2010;52(4):213–6.
31. Hsia CC, Raskin P. The diabetic lung: relevance of alveolar microangiopathy for the use of inhaled insulin. Am J Med. 2005;118(3):205–11.
32. Tai H, Wang MY, Zhao YP, Li LB, Jiang XL, Dong Z, Lv XN, Liu J, Dong QY, Liu XG, Kuang JS. Pulmonary function and retrobulbar hemodynamics in subjects with type 2 diabetes mellitus. Respir Care. 2017;62(5):602–14.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.